Overview
The aim of this study is to compare plasma S Protein levels to SARS-CoV-2 viral load in COVID positive patients.
Description
Non-pharmacological, non-interventional, prospective, monocentric study involving the use of biological materials.
There will be two cohorts:
- COVID + cohort: 50 patients with positive nasopharyngeal swab and / or BAL.
- Control Cohort: 20 patients with non-SARS-CoV-2 related pneumonia.
The study involves analyzing biological samples collected for normal clinical practice.
In particular:
- blood samples will be used for PROS and Sflt1 assay, haematological, biochemical and coagulation tests.
- Samples deriving from nasopharyngeal swab or from Broncho-Alveolar Lavage (BAL) liquid will be used for Real time PCR analysis to evaluate the viral load of SARS CoV-2.
Eligibility
Inclusion Criteria:
Cohort COVID + :
- Subjects aged ≥ 18 years.
- Signing of the informed consent.
- Positivity for SARS-CoV-2 by RealTimePCR from nasopharyngeal swab or bronchial wash.
Cohort Control:
- Subjects aged ≥ 18 years.
- Signing of the informed consent.
- Diagnosis of pneumonia not related to SARS-CoV-2, demonstrated by negative swab.
Exclusion Criteria:
- Patients with a diagnosis of congenital S Protein deficiency.
- Patients who are taking oral anticoagulant therapy (TAO) or new oral anticoagulants (NAO).
- Chronic liver failure (> 5 points on the Child-Pugh score).
- Female subjects who are pregnant or on estrogen-progestogen replacement therapy.